ECE2009 Poster Presentations Endocrine tumours and neoplasia (53 abstracts)
Moscow Regional Research Clinical Institute, Moscow, Russian Federation.
In 24 years old woman in March 2007 was diagnosed acromegaly (somatoprolactinoma) an active phase, hyperprolactinemia. Manifestations: rugged features, amenorrhea, galactorrhea, fasting GH 144 ng/ml (N<10 ng/ml), IGF-1 586 ng/ml (N 48450 ng/ml), PRL 6726 mU/l (N 40530 mU/l). According to pituitary MRT a tumor volume was 14.4 cm3, with supra- and infrasella growth. She was operated in May 2007: transnal transsphenoidal subtotal removal of the pituitary adenoma. After adenomectomia: GH nadir in OGTT was 28.1 mU/l (N<2.7 mU/l), IGF-1 952 ng/ml, PRL 111 mU/l. Pituitary MRT: endo- and parasella adenoma components 5.7 cm3 volume. Galactorrhea persists. Long acting somatostatin (Oktreotid-depot) was prescribed in July 2007 in start dose 20 mg/month, and it was increased in Sept 2007 to 30 mg to suppress GH secretion (GH nadir 26.4 mU/l, IGF-1 601 ng/ml). Oktreotid-depot treatment induced a reduction in volume postoperative adenoma components from 5.7 cm3 to 4.5 cm3. After 4th Oktreotid-depot injection (30 mg/m) 24 weeks pregnancy has been diagnosed. Oktreotid-depot treatment has been continued up to physiological childbirth at 40th weeks. The child was healthy: weight 3 250 g, growth 52 cm, 9 points on Apgar scale. Acromegaly signs did not worsen during pregnancy and after childbirth.